Clinical-stage gut health company Atmo Biosciences has announced the publication of a clinical study supporting its Gas Capsule’s ability to determine its location in the gastrointestinal tract.
The company said the study demonstrates strong agreement between data from the Gas Capsule and a validated, FDA-cleared Wireless Motility Capsule (WMC), in determining transit metrics in healthy subjects.
Atmo said it now intends to conduct a clinical trial in patients with gastrointestinal motility disorders.
The paper, which is entitled 'Comparison of gastrointestinal landmarks using the gas-sensing capsule and wireless motility capsule', has been published in the journal Alimentary Pharmacology and Therapeutics.
Atmo’s Gas Capsule uses different sensor technologies to the WMC. However, according to the company, both devices resulted in excellent observer agreement for the identification of key anatomical landmarks and for measurements of gut motility and transit time.
Based on the positive data from the study, Atmo said it intends to initiate a similar clinical trial in patients with gastrointestinal motility disorders to demonstrate the clinical utility of its Gas Capsule.
Atmo CEO and managing director Malcolm Hebblewhite said, “Data from this study has provided us with the confidence to progress to a study involving patients who suffer from the motility disorders that we are aiming to diagnose. We are very excited to be working with key opinion leading gastroenterologists who specialise in functional gut disorders to support the upcoming study."